Jaren Janghorbani is head of the Complex Commercial Litigation group, co-chair of the M&A Litigation practice, and a member of the Paul, Weiss Executive Committee. A nationally recognized trial lawyer and litigation strategist, her practice is concentrated on complex commercial litigation, with a focus on M&A and governance-related disputes, including shareholder activism and proxy contest defense, high-stakes shareholder litigation, and significant large-scale torts, including environmental disputes. She has tried multiple multibillion-dollar cases and favorably resolved numerous others, representing a diverse range of clients including global public companies, boards of directors and special board committees, senior executives, and private equity firms and their portfolio companies across the industrials, energy, technology, media & entertainment and pharmaceuticals sectors.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2027 Lawdragon 500 Leading Litigators in America | 2027 | Complex Commercial Litigation, esp. M&A |
| The 2026 Lawdragon 500 Leading Lawyers in America | 2026 | Litigation, esp. M&A |
| The 2026 Lawdragon 500 Leading Litigators in America | 2026 | Complex Commercial Litigation, esp. M&A |
| The 2025 Lawdragon 500 Leading Lawyers in America | 2025 | Litigation, esp. M&A |
| The 2025 Lawdragon 500 Leading Litigators in America | 2025 | Complex Commercial Litigation, esp. M&A |
| The 2024 Lawdragon 500 Leading Lawyers in America | 2024 | Litigation, esp. M&A |
| The 2024 Lawdragon 500 Leading Litigators in America | 2024 | Complex Commercial Litigation, esp. M&A |
| The 2023 Lawdragon 500 Leading Lawyers in America | 2023 | Litigation, esp. M&A |
| The 2022 Lawdragon 500 Leading Lawyers in America | 2022 | Litigation, esp. M&A |
| Lawdragon 500 Leading Litigators in America | 2022 | Complex Commercial Litigation, esp. M&A |
| The 2021 Lawdragon 500 Leading Lawyers in America | 2021 | Litigation, esp. M&A |
Janghorbani advises clients on complex mergers and acquisitions and corporate governance disputes, including high-stakes shareholder class actions challenging multibillion-dollar transactions, material adverse event litigations, and corporate control disputes in the Delaware Court of Chancery and federal and state courts nationwide. She has also successfully counseled numerous public company boards of directors and special committees through various transaction-related disputes. Jaren’s experience includes representing:
- The former independent directors of CBS Corp. in successfully resolving multiple multibillion-dollar securities class and derivative actions in the Delaware Court of Chancery arising from the stock-for-stock merger of CBS and Viacom.
- Metsera, a clinical-stage biopharmaceutical company, in litigation related to its $10 billion acquisition by Pfizer, including winning the denial of a motion for temporary restraining order filed by Pfizer in the Delaware Court of Chancery attempting to block Novo Nordisk’s unsolicited bid for Metsera.
- The former special committee members of Cornerstone Building Brands in the successful settlement of shareholder litigation in the Delaware Court of Chancery challenging the fairness and sufficiency of disclosures relating to a take-private transaction, in which Cornerstone’s majority shareholder, Clayton, Dubilier & Rice, acquired the remaining outstanding shares of Cornerstone.
- The special committee and additional independent directors of Expedia Group in successfully resolving a multi-year litigation and internal investigation of claims in a shareholder derivative breach of fiduciary duty class action in the Delaware Court of Chancery related to Expedia’s $2.6 billion acquisition of Liberty Expedia Holdings.
- Symbiont.io, Inc., a blockchain-powered “smart securities” start-up, in winning a more than $140 million trial verdict in the Delaware Court of Chancery in a suit brought against Ipreo Holdings and IHS Markit concerning a joint venture intended to leverage blockchain technology in the syndicated loan market.
- The special committee of Pilgrim’s Pride Corporation in the successful defense of shareholder breach of fiduciary duty derivative litigation in the Delaware Court of Chancery related to Pilgrim Pride’s $1.3 billion acquisition of Moy Park from JBS SA.
- Moelis & Company LLC, Archer Aviation Inc. and various related entities, directors and officers in a class action pending in the Delaware Court of Chancery related to the de-SPAC merger between Moelis and Archer.
Janghorbani regularly represents clients in a variety of complex commercial disputes, large-scale torts and environmental liability litigations, trade secrets actions, and securities fraud litigations. Among others, she has represented:
- Solvay Specialty Polymers USA in a constellation of state and federal court litigations involving claims for personal injury, medical monitoring, biomonitoring and natural resource damages related to PFAS chemicals, including as trial counsel in securing a landmark $394 million settlement of an environmental liability lawsuit brought by the New Jersey Department of Environmental Protection (NJDEP), the commissioner of the NJDEP and the administrator of the New Jersey Spill Compensation Fund.
- Atos SE in several high-value commercial disputes, including in the successful settlement and dismissal, with prejudice, of a lawsuit brought by Unisys Corp. alleging misappropriation of trade secrets.
- Citigroup in defense of claims brought in New Jersey state court arising out of the collapse of Parmalat, defeating claims worth more than $10 billion and achieving a $364 million counterclaim jury verdict for Citigroup—among the largest defense-side verdicts in the history of New Jersey.
- Merck in class action and other related litigation related to Vioxx..
